CNS Pharmaceuticals and WPD Pharmaceuticals Identify Leading Polish Medical Institutions for Berubicin Phase 2 Clinical Trial

HOUSTON, April 30, 2020 /PRNewswire/ — CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system in collaboration with WPD Pharmaceuticals Inc. (CSE:WBIO) (8SV1.F) (“WPD”) a clinical stage pharmaceutical company, today announced it has identified several leading medical institutions in Poland to conduct its Berubicin Phase 2 clinical trial in adults with glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer.

The release as fetched from its publisher. cnspharma.com ↗